Loading...
Please wait, while we are loading the content...
Similar Documents
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures.
| Content Provider | Europe PMC |
|---|---|
| Author | Lattanzi, Simona Ascoli, Michele Canafoglia, Laura Paola Canevini, Maria Casciato, Sara Cerulli Irelli, Emanuele Chiesa, Valentina Dainese, Filippo De Maria, Giovanni Didato, Giuseppe Di Gennaro, Giancarlo Falcicchio, Giovanni Fanella, Martina Gangitano, Massimo La Neve, Angela Mecarelli, Oriano Montalenti, Elisa Morano, Alessandra Piazza, Federico Pizzanelli, Chiara Pulitano, Patrizia Ranzato, Federica Rosati, Eleonora Tassi, Laura Di Bonaventura, Carlo Ventura, Maria |
| Abstract | AbstractThe maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real‐world practice. Patients with focal epilepsy prescribed add‐on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12‐month follow‐up. Nine hundred ninety‐four patients with a median age of 45 (interquartile range = 32–56) years were included. During the 1‐year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure‐free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12 months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9311068&blobtype=pdf |
| Page Count | 9 |
| ISSN | 00139580 |
| Journal | Epilepsia |
| Volume Number | 63 |
| DOI | 10.1111/epi.17223 |
| PubMed Central reference number | PMC9311068 |
| Issue Number | 5 |
| PubMed reference number | 35278335 |
| e-ISSN | 15281167 |
| Language | English |
| Publisher | John Wiley and Sons Inc. |
| Publisher Date | 2022-03-26 |
| Publisher Place | Hoboken |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy |
| Subject Keyword | antiseizure medication brivaracetam focal seizures seizure freedom sodium channel blockers |
| Content Type | Text |
| Resource Type | Article |
| Subject | Neurology Neurology (clinical) |
